Katharina Huber, Albert Giralt, René Dreos, Helene Michenthaler, Sarah Geller, Valentin Barquissau, Dorian V Ziegler, Daniele Tavernari, Hector Gallart-Ayala, Katarina Krajina, Katharina Jonas, Giovanni Ciriello, Julijana Ivanisevic, Andreas Prokesch, Martin Pichler, Lluis Fajas
Metabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation of how E2F1 loss impacts metabolic pathways related to cancer progression...
April 3, 2024: Biochimica et Biophysica Acta. Molecular Cell Research